The specific HDAC targets regulated by EWSR1-FLI1 activity provide advantages to EWS tumor cells, and blockade of this regulation via HDAC inhibition could specifically sensitize EWS cells to BML-281 treatment. The gene discussed is HDAC9; the disease is neoplasm.